OMEGA: a prospective, randomised, double-blind, placebo-controlled multicentre study in patients who survived acute myocardial infarction to investigate the efficacy and safety of 1 gram omega-3-fatty acid ethyl esters (omega-3FAE) daily versus placebo to reduce the risk of sudden cardiac death

Trial Profile

OMEGA: a prospective, randomised, double-blind, placebo-controlled multicentre study in patients who survived acute myocardial infarction to investigate the efficacy and safety of 1 gram omega-3-fatty acid ethyl esters (omega-3FAE) daily versus placebo to reduce the risk of sudden cardiac death

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Myocardial infarction; Sudden death
  • Focus Therapeutic Use
  • Acronyms OMEGA
  • Most Recent Events

    • 30 Mar 2009 Results reported at the 58th Annual Scientific Session of the American College of Cardiology (ACC 2009), as reported by Pronova BioPharma.
    • 30 Mar 2009 Results were presented as a late-breaking clinical trial during the 58th Annual Scientific Session of the American College of Cardiology (ACC 2009).
    • 26 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top